Business Context and Reporting Period
This Form 8-K filing by Fluidigm Corporation (noted as Standard BioTools Inc. in metadata) is dated August 4, 2016. The report discloses the appointment of a new executive officer effective August 1, 2016.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- Base Salary: $450,000 per year.
- Target Bonus: 60% of base salary (subject to performance objectives).
- Equity Grant: Option to purchase 140,000 shares and 14,000 restricted stock units (RSUs).
Material Changes
The primary material change is the appointment of Stephen Christopher Linthwaite as President and Chief Operating Officer. Mr. Linthwaite reports to CEO Gajus V. Worthington. He previously held various managerial positions at Thermo Fisher Scientific Inc. and Life Technologies Corporation.
Guidance, Outlook, and Compensation Details
The filing details the terms of Mr. Linthwaite's employment and severance agreement:
- Equity Vesting: The stock option vests 25% on August 1, 2017, with the balance vesting ratably over the following 36 months (fully vested by August 1, 2020). RSUs vest subject to performance conditions.
- Severance: In the event of termination without "cause" or resignation for "good reason" outside the change of control window, Mr. Linthwaite is entitled to 12 months of base salary plus the target annual bonus.
- Change of Control: If termination occurs within 90 days prior to or 12 months after a change of control, severance is based on the greater of salary/bonus at the time of the change of control or termination. Additionally, equity awards fully vest upon qualifying termination during this period.
- Benefits: Up to 12 months of medical, dental, and vision benefit reimbursement is available for qualifying terminations.
Investor Verification Checklist
- Verify the full text of the offer letter and severance agreement, which are scheduled to be filed in the Form 10-Q for the quarter ending September 30, 2016.
- Confirm the specific performance conditions attached to the 14,000 RSU grant.
- Review the definition of "good reason" in the severance agreement, which includes the appointment of a new CEO other than Mr. Linthwaite within the first 24 months of his employment.
- Monitor the impact of this executive appointment on the company's strategic direction in the life sciences sector.